nach oben

Erschienen in:

2018 | OriginalPaper | Buchkapitel

An Introduction to „Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins“

verfasst von : Michael Pohlscheidt, Robert Kiss, Uwe Gottschalk

Erschienen in: New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The production of the first therapeutic proteins in the early 1980s heralded the launch of the biopharmaceuticals industry. The number of approved products has grown year on year over the past three decades to now represent a significant share of the entire pharmaceuticals market. More than 200 therapeutic proteins have been approved, approximately a quarter of which are represented by monoclonal antibodies and their derivatives. In 2016, the list of the top 15 best-selling drugs included more than eight biologics and in 2020 the trend will continue, with more than 50% of the top 20 best-selling drugs predicted to be biologics. From 1986 to 2014 several first-in-class, advance-in-class, and breakthrough designated therapeutic options were approved, with advanced therapies such as immuno-oncology and cell-based therapies being approved for several indications.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Nächstes Kapitel New Mammalian Expression Systems

Reichert JM (2001) Monoclonal antibodies in the clinic. Nat Biotechnol 19:819–822CrossRefPubMed

Reichert JM, Pavolu A (2004) Monoclonal antibodies market. Nat Rev Drug Discov 3:383–384CrossRefPubMed

Drapeau M, Sullivan F, Moniz Carpenter J (2007) Special report: blockbuster then and now–trends for billion-dollar drugs. Spectr Ther Markets Emerg Technol 12:1–39

Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev 8:959–968

Doig AR, Ecker DM, Ransohoff TC (2015) Monoclonal antibody targets and indications. Am Pharm Rev 15:177490

Ecker DM, Dana Jones S, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14CrossRefPubMed

Choi JH, Lee SY (2004) Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 64(5):625–635CrossRefPubMed

Baneyx F, Mujacic M (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 22(11):1399–1408CrossRefPubMed

Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398CrossRefPubMed

10.

Sethuramann N, Stadheim TA (2006) Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17(4):341–346CrossRef

11.

Heath C, Kiss R (2007) Cell culture process development: advances in process engineering. Biotechnol Prog 23:46–51CrossRefPubMed

12.

Su WW (2003) Bioreactors, perfusion. Encyclopedia of cell technology. Wiley, New York, pp 978–993

13.

Shukla A, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261CrossRefPubMed

14.

Kompala D, Ozturk S (2006) Optimization of high density perfusion bioreactors. In: Oztuk S, Hu W-S (eds) Cell culture technology for pharmaceutical and cellular therapies. Taylor and Francis, New York, pp 349–416

15.

Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A (2003) Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82(7):751–765CrossRefPubMed

16.

Ryll T, Dutina G, Reyes A, Gunson J, Krummen L, Etcheverry T (2000) Performance of small scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: characterization of separation efficiency and impact of perfusion on product quality. Biotechnol Bioeng 69(4):440–449CrossRefPubMed

17.

Woodside SM, Boweb BD, Piret JM (1998) Mammalian cell retention devices for stirred perfusion bioreactors. Cytotechnology 28:163–175CrossRefPubMedPubMedCentral

18.

Castillo RC, Medrohno RA (2004) Cell retention devices for suspended-cell perfusion cultures. In: Scheper T (ed) Adv Biochem Eng Biotechnol 74:129–169

19.

Griffiths JB (1992) Animal cell culture processes—batch or continuous? J Biotechnol 22:21–30CrossRefPubMed

20.

Wang Z, Tan W, Poptic EJ, Belovich J. Feasibility of using a small-scale perfusion bioreactor with a novel cell retention device to inoculate a large-scale bioreactor. In: Conference presentation at the American Chemical Society national meeting, San Francisco, CA

21.

Chu L, Robinson DK (2001) Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 12(2):180–187CrossRefPubMed

22.

Gagnon P (2012) Technology trends in antibody purification. J Chromatogr A 1221:57–70CrossRefPubMed

23.

Jungbauer A (2013) Continuous downstream processing of biopharmaceuticals. Trends Biotechnol 31:479–492CrossRefPubMed

24.

Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345–352CrossRefPubMed

25.

Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13(1):65–93CrossRefPubMed

26.

Lalonde ME, Durocher Y (2017) Therapeutic glycoprotein production in mammalian cells. J Biotechnol 251:128–140CrossRefPubMed

27.

Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13(3):245–255CrossRefPubMed

28.

Mullard A (2013) Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discov 12(5):329–332CrossRefPubMed

29.

Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J (2017) Immunotoxin: a new tool for cancer therapy. Tumour Biol 39(2):1–11, 1010428317692226

30.

Allied Market Research (2014) World biosimilars/follow-on-biologics market—opportunities and forecasts, 2013–2020. Allied Market Research, Portland

31.

Gottschalk U, Brorson K, Shukla AA (2012) The need for innovation in biomanufacturing. Nat Biotechnol 30(6):489–492CrossRefPubMed

32.

Gutierrez JM, Lewis NE (2015) Optimizing eukaryotic cell hosts for protein production through systems biotechnology and genome-scale modeling. Biotechnol J 10(7):939–949CrossRefPubMed

33.

Shukla AA, Gottschalk U (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol 31(3):147–154CrossRefPubMed

34.

Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM (2010) Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 44(1):41–47CrossRefPubMed

35.

Buyel JF, Twyman RM, Fischer R (2017) Very-large-scale production of antibodies in plants: the biologization of manufacturing. Biotechnol Adv 35:458–665CrossRefPubMed

36.

Rathore AS (2016) Quality by design (QbD)-based process development for purification of a biotherapeutic. Trends Biotechnol 34(5):358–370CrossRefPubMed

37.

Pohlscheidt M, Jacobs M, Wolf S, Thiele J, Jockwer A, Gabelsberger J, Jenzsch M, Tebbe H, Burg J (2013) Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors. Biotechnol Prog 29(1):222–229CrossRefPubMed

Titel: An Introduction to „Recent Trends in the Biotechnology Industry: Development and Manufacturing of Recombinant Antibodies and Proteins“
verfasst von: Michael Pohlscheidt
Robert Kiss
Uwe Gottschalk
Verlag: Springer International Publishing
Buch: New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins
Print ISBN: 978-3-319-97108-7

Electronic ISBN: 978-3-319-97110-0

Copyright-Jahr: 2018
DOI: https://doi.org/10.1007/10_2017_39

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht